Nonvalvüler Atriyal Fibrilasyon Hastalarında Dabigatran Tedavisinin Trombosit Hacim İndeksleri ve Trombosit Sayısı Üzerine Etkileri

Year 2020, Volume: 7 Issue: 3, 373 - 376, 30.09.2020

Ferhat Özyurtlu Nurullah Çetin

https://doi.org/10.34087/cbusbed.710032

Cited By: 1

Abstract

Amaç: Çalışmamızda, nonvalvüler atriyal fibrilasyon tedavisinde kullanılan Dabigatranın trombosit indeksleri üzerindeki etkisini araştırmayı amaçladık.
Materyal ve Metod: Çalışmamıza ocak 2018 ve aralık 2019 tarihleri arasında kardiyoloji polikliniğine başvurup, non valvüler atriyal fibrilasyon tanısı ile endikasyon dahilinde dabigatran tedavisi başlanmış 69 hasta dahil edilmiştir. Hastaların dosyaları taranarak dabigatran başlanmadan önceki ve tedavi altında 6 ay sonraki laboratuar parametreleri değerlendirmeye alındı.
Bulgular: Çalışmaya 69 hasta dahil edilidi. Yaş ortalaması 69 ± 9 olup, hastaların %62.3’si kadın, %37.7’si erkek idi. Hastaların %87’sinde hipertansiyon, %26.1’inde diabetes mellitus, %17.4’ünde dislipidemi mevcuttu. 6 aylık dabigatran kullanımı sonrasında, başta MPV olmak üzere, platalet sayısı ve diğer trombosit indekslerinde anlamlı bir değişiklik saptanmadı.
Sonuç: 6 aylık bir tedavi periyodunda dabigatranın MPV başta olmak üzere, trombosit sayısı ve diğer platelet indeksleri üzerinde anlamlı bir değişikliğe yol açmadığını gözlemledik. Çalışma verilerimiz ışığında Dabigatran’ın AF’de inme ve tromboembolinin önlenmesinde, platelet indeksleri üzerine olan etkisinin bir anlam ifade etmediği görülmektedir.

Keywords

Dabigatran, Nonvalvüler Atriyal Fibrilasyon, Mean Platelet Volüm, inme

References

• 1. Wolf, P.A., R.D. Abbott, and W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991. 22(8): p. 983-8.
• 2. Ruff, C.T., et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014. 383(9921): p. 955-62.
• 3. Camm, A.J., et al., Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol, 2011. 58(5): p. 493-501.
• 4. Rienstra, M., et al., Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail, 2013. 1(1): p. 21-8.
• 5. January, C.T., et al., 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation, 2019. 140(2): p. e125-e151.
• 6. Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009. 361(12): p. 1139-51.
• 7. Korniluk, A., et al., Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm, 2019. 2019: p. 9213074.
• 8. Fateh-Moghadam, S., et al., Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost, 2007. 97(6): p. 974-8.
• 9. Han, J.Y., et al., Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets, 2013. 24(5): p. 401-6.
• 10. Vizioli, L., S. Muscari, and A. Muscari, The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract, 2009. 63(10): p. 1509-15.
• 11. Ozkan, B., et al., Relationship between mean platelet volume and atherosclerosis in young patients with ST elevation myocardial infarction. Angiology, 2013. 64(5): p. 371-4.
• 12. Benjamin, E.J., et al., Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998. 98(10): p. 946-52.
• 13. Colkesen, Y., et al., Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis, 2008. 19(5): p. 411-4.
• 14. Choudhury, A., et al., Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol, 2007. 49(19): p. 1957-64.
• 15. Butterworth, R.J. and P.M. Bath, The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets, 1998. 9(6): p. 359-64.
• 16. Bath, P., et al., Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke, 2004. 35(3): p. 622-6.
• 17. Providencia, R., et al., Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord, 2013. 13: p. 40.
• 18. Turfan, M., et al., Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients. Blood Coagul Fibrinolysis, 2013. 24(1): p. 55-8.
• 19. Bayar, N., et al., Usefulness of mean platelet volume for predicting stroke risk in paroxysmal atrial fibrillation patients. Blood Coagul Fibrinolysis, 2015. 26(6): p. 669-72.
• 20. Guthikonda, S., et al., Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol, 2008. 52(9): p. 743-9.
• 21. Arik, O.Z., et al., Relationship between platelet indices and international normalized ratio in patients with non-valvular atrial fibrillation. Platelets, 2014. 25(5): p. 311-6.
• 22. Duzen, I.V., et al., Effect of new oral anticoagulants on platelet indices in non-valvular atrial fibrillation patients. Herz, 2019.